OVERPRODUCTION OF PROINFLAMMATORY CYTOKINES IMBALANCED BY THEIR ANTAGONISTS IN POEMS SYNDROME

Citation
Rk. Gherardi et al., OVERPRODUCTION OF PROINFLAMMATORY CYTOKINES IMBALANCED BY THEIR ANTAGONISTS IN POEMS SYNDROME, Blood, 87(4), 1996, pp. 1458-1465
Citations number
55
Categorie Soggetti
Hematology
Journal title
BloodACNP
ISSN journal
00064971
Volume
87
Issue
4
Year of publication
1996
Pages
1458 - 1465
Database
ISI
SICI code
0006-4971(1996)87:4<1458:OOPCIB>2.0.ZU;2-P
Abstract
The polyneuropathy, organomegaly, endocrinopathy, M protein, skin chan ges (POEMS) syndrome is a rare multisystem disorder of obscure pathoge nesis associated with osteosclerotic myeloma. Circulating levels of pr oinflammatory cytokines (tumor necrosis factor-alpha [TNF-alpha] inter leukin-1 beta [IL-1 beta], IL-2, IL-6, and interferon gamma [IFN gamma ]), anti-inflammatory cytokines (transforming growth factor beta(1) [T GF beta(1)], IL-4, IL-10, and IL-13), the cytokine carrier protein alp ha 2macroglobulin, IL-1 receptor antagonist (IL-1ra), soluble TNF rece ptors (sTNFr) p55 and p75, and soluble IL-6 receptor (sIL-6r) were det ermined in 15 patients with POEMS syndrome and 15 with multiple myelom a. Patients with POEMS syndrome had higher serum levels of IL-1 beta, TNF-alpha, and IL-6 and lower serum levels of TGF beta(1) than did pat ients with multiple myeloma. Serum levels of IL-2, IL-4, IL-10, IL-13, IFN gamma, alpha 2macroglobulin, and sIL-6r were similar in both grou ps. IL-1ra and sTNFrs were increased in POEMS syndrome, but out of pro portion to the increase of IL-1 beta and TNF-alpha. Serial evaluations in 1 patient showed that proinflammatory cytokine serum levels parall eled disease activity assessed by platelet count and neurologic involv ement. Our results suggest that the manifestations of POEMS syndrome m ight be regarded as the result of a marked activation of the proinflam matory cytokine network (IL-1 beta, IL-6, and TNF-alpha) associated wi th a weak or even decreased (TGF beta 1) antagonistic reaction insuffi cient to counteract the noxious effects of cytokines. (C) 1996 by The American Society of Hematology.